When you buy through our links, we may earn a commission. Learn more› By Wirecutter Staff The OXO Brew 9 Cup Coffee Maker is now our top-pick drip coffee maker, replacing the Bonavita Enthusiast ...

The Roche Bobois bubble couch and its dupes. The “Cloud.” Couches with seats so deep you are basically buying a bed and surrendering precious living-room space where you might otherwise put a coffee ...

Source: FactSet Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet ...

With winter approaching, now’s the time to prepare your home for holiday gatherings with Roche Bobois’ exclusive, custom-made furniture. From elegant sofas to stylish cocktail tables ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy delivery technology, which synthesizes virus capsids with better functionality ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

Speaking to the press Wednesday, Roche’s chief executive Thomas Schinecker critiqued the proposed transaction, arguing that it could hamper the ability of smaller biopharma players to lock down ...

Swiss Pharmaceutical giant Roche Holding (OTCQX:RHHBY) (OTCQX:RHHBF) on Wednesday reaffirmed its full-year sales and earnings outlook after the company’s third-quarter sales results exceeded ...

Roche doesn’t think so. “I think we don’t see anything that should be slowing Vabysmo momentum down,” Teresa Graham, CEO of Roche Pharmaceuticals, said during a press conference Wednesday ...

FRANKFURT, Oct 23 (Reuters) - The CEO of Roche (ROG.S), opens new tab said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the ...

Roche Bobois SAS (FR:RBO) has released an update. Roche Bobois SA reported a slight decline in third-quarter revenue to €96.2 million, down 2.2% from the previous year, but saw a 3.4% growth in ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.